| Hyperparathyroidism, Secondary
Parsabiv vs Rayaldee
Side-by-side clinical, coverage, and cost comparison for hyperparathyroidism, secondary.Deep comparison between: Parsabiv vs Rayaldee with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRayaldee has a higher rate of injection site reactions vs Parsabiv based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayaldee but not Parsabiv, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Parsabiv
Rayaldee
At A Glance
IV injection
Three times per week
Calcimimetic agent
Oral
Daily
Vitamin D3 analog
Indications
- Hyperparathyroidism, Secondary
- Hyperparathyroidism, Secondary
Dosing
Hyperparathyroidism, Secondary Starting dose 5 mg IV bolus three times per week at end of hemodialysis; maintenance dose individualized by titration, range 2.5 to 15 mg three times per week.
Hyperparathyroidism, Secondary Initial dose 30 mcg orally once daily at bedtime; increase to 60 mcg once daily after approximately 3 months if intact PTH remains above the desired therapeutic range.
Contraindications
- Known hypersensitivity to etelcalcetide or any of its excipients
—
Adverse Reactions
Most common (>=5%) Blood calcium decreased, muscle spasms, diarrhea, nausea, vomiting, headache, hypocalcemia, paresthesia
Serious Hypocalcemia, worsening heart failure, upper gastrointestinal bleeding, adynamic bone
Postmarketing Anaphylactic reaction, hypocalcemia with concomitant calcium-lowering agents, seizures secondary to hypocalcemia
Most common (>=1.4%) Anemia, Nasopharyngitis, Blood creatinine increased, Dyspnea, Cough, Cardiac failure congestive, Constipation, Bronchitis, Hyperkalemia, Osteoarthritis, Hyperuricemia, Contusion, Pneumonia, Chronic obstructive pulmonary disease
Serious Hypercalcemia, Adynamic Bone Disease
Pharmacology
Etelcalcetide is a calcimimetic agent that allosterically modulates the calcium-sensing receptor (CaSR), enhancing activation by extracellular calcium to decrease PTH secretion from parathyroid chief cells.
Calcifediol is a prohormone of vitamin D3 that is converted by CYP27B1 in the kidney to calcitriol, which binds to the vitamin D receptor and activates pathways that increase intestinal absorption of calcium and phosphorus and reduce parathyroid hormone synthesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Parsabiv
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Rayaldee
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Parsabiv
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Rayaldee
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Parsabiv
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Rayaldee
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAmgen Safety Net Foundation
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableHealthWell: Secondary Hyperparathyroidism
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ParsabivView full Parsabiv profile
RayaldeeView full Rayaldee profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.